[New systemic antifungal drugs: mechanisms of action, drug interactions and side effects].

摘要: New antifungal agents are needed to match the currently increasing rate of systemic fungal infections and development resistant strains. This appears possible by introduction second generation azole antifungals which potently inhibit ergosterol synthesis, but also a partial synthetic echinocandin analogue acts suppression enzyme glucan synthase. Voriconazole caspofungin have been approved for treatment invasive aspergillosis. Both drugs well tolerated if contraindications and--with voriconazole--also drug interactions respected. Possibly these suitable other severe including oropharyngeal candidosis in immunocompromised host.